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Abstract Cardiomyocyte death is now recognized as a
critical factor in the development of heart disease. Mito-
chondria are not only responsible for energy production to
ensure that cardiac output meets the body’s energy
demands, but they serve as critical integrators of cell
survival signals. Numerous stressors are known to induce
cell death by necrosis and/or apoptosis mediated through
mitochondrial dysregulation. Anti- and pro-apoptotic Bcl-2
family proteins regulate apoptosis by controlling mitochon-
drial outer membrane permeability, whereas opening of the
mitochondrial permeability transition pore (PT-pore) indu-
ces large amplitude permeability of the inner membrane and
consequent rupture of the outer membrane. Akt is one of
the best described survival kinases activated by receptor
ligands and its activation preserves mitochondrial integrity
and protects cardiomyocytes against necrotic and apoptotic
death. The mechanisms responsible for Akt-mediated
mitochondrial protection have not been fully elucidated.
There is, however, accumulating evidence that multiple Akt
target molecules, recruited through both transcriptional and
post-transcriptional mechanisms, directly impinge upon and
protect mitochondria. In this review we discuss mecha-
nisms by which Akt activation can effect changes at the
mitochondria that protect cardiomyocytes and attenuate
pathophysiological responses of the heart.
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Introduction
As a result of symbiotic invasion of eukaryotes by
eubacteria more than 1.5 billion years ago, mitochondria
have evolved to become the critical organelles for genera-
tion of cellular energy (Dyall et al. 2004) as well as
gatekeepers in the control of cell survival (Kroemer et al.
2007). Heart tissue is amongst the most rich in mitochon-
dria as there are profound energy demands on oxidative
phosphorylation to support the beat-to-beat contraction/
relaxation cycle. Adult cardiomyocytes do not proliferate
and accordingly their loss through cell death plays a crucial
role in heart diseases involving ischemic injury and the
development of heart failure (Adams et al. 2000; Dorn and
Brown 1999; Gustafsson and Gottlieb 2008; Hayakawa et
al. 2003; Murphy and Steenbergen 2008; Nakagawa et al.
2005; Nakayama et al. 2006; Scarabelli et al. 2006; Weiss
et al. 2003; Yussman et al. 2002). It has become apparent in
recent years that Bcl-2 family proteins and the permeability
transition pore (PT-pore) are important regulators of the
mitochondrial death pathway that is activated by stress in
cardiomyocytes (Gustafsson and Gottlieb 2008; Halestrap
and Pasdois 2009; Murphy and Steenbergen 2008). The
proapoptotic Bcl-2 family proteins induce mitochondrial
outer membrane permeabilization (MOMP) (Reed 2008).
Opening of the PT-pore at the inner membrane causes
mitochondrial depolarization, the loss of small molecular
weight substances from the matrix, and rupture of the outer
mitochondrial membranes due to osmotic mitochondrial
swelling (Baines et al. 2005; Crompton 1999; Crow et al.
2004; Green 2005; Green and Kroemer 2004; Gustafsson
and Gottlieb 2003; Nakagawa et al. 2005; Weiss et al.
2003). The consequences of activation of these two path-
ways are reported to be different, and their interrelationship
remains somewhat controversial. Bcl-2 family proteins are
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now believed to more specifically regulate apoptosis
(Baines et al. 2005; Green 2005; Nakagawa et al. 2005).
MOMP induced by apoptotic Bcl-2 family proteins leads
to release of apoptotic molecules such as cytochrome c,
leading to caspase-9/caspase-3 activation and DNA
fragmentation. In contrast, the PT-pore is primarily
associated with necrotic death (Baines et al. 2005;
Nakagawa et al. 2005). Both apoptotic and necrotic cell
death have been observed in the heart subjected to ischemic
injury, in congestive heart failure and in cardiomyopathy,
although the contribution of these two types of death is
controversial and may differ depending on the types and
pathological stages of stress. Regardless, preservation of
mitochondrial integrity is essential not only to mainte-
nance of metabolic homeostasis but also to survival of
cardiomyocytes.
Protective signaling molecules are recruited in response
to stress to prevent cell death. Akt is a serine/threonine
kinase with well documented targets controlling diverse
cellular functions, including protein synthesis, energy
metabolism and cellular survival (Ceci et al. 2007; Fujio
et al. 2000; Matsui et al. 1999; Matsui et al. 2001).
Preservation of mitochondrial integrity has been shown to
be involved in Akt-mediated protection (Lai et al. 2003;
Miyamoto et al. 2008; Plas et al. 2001) and recent studies
reveal that Akt has direct inhibitory effects not only on
apoptotic Bcl-2 family proteins but also on the PT-pore
(Ahmad et al. 2006; Davidson et al. 2006; Juhaszova et al.
2004; Miyamoto et al. 2008). Interestingly it is becoming
increasingly clear that survival/death signaling and met-
abolic signaling share regulatory molecules as evidenced
for example, by an unexpected physiological role of
BAD, an Akt target molecule, on glucose metabolism in
β-cells (Danial et al. 2008). Other molecules recently
reported as regulators of Akt mediated mitochondrial protec-
tion include glycogen synthase kinase 3 (GSK-3) and
hexokinase-II. The mechanisms by which Akt confers
mitochondrial protection in the heart will be discussed
below.
Cardiac injury, mitochondria and the PT-pore
An increase in intracellular Ca2+ is responsible for normal
cardiomyocyte contraction. In turn, mitochondrial Ca2+
increases in a beat-to-beat fashion in response to cytosolic
Ca2+ transients and stimulates ATP production to meet
energy demands via activation of Ca2+-sensitive matrix
dehydrogenases (Maack and O’Rourke 2007; Szalai et al.
2000). It has been established that cardiomyocyte injury
induced by ischemia/reperfusion (I/R) results from in-
creased cytosolic Ca2+ and generation of reactive oxygen
species (ROS). As a result of loss of ionic homeostasis
during ischemia, supra-physiological levels of cytoplasmic
Ca2+ lead to mitochondrial Ca2+ overload during reperfu-
sion. The combination of mitochondrial Ca2+ overloading,
oxidative stress, and the loss of adenine nucleotides
potentiates opening of the mitochondrial PT-pore (Crow et
al. 2004; Gustafsson and Gottlieb 2003; Murphy and
Steenbergen 2008; Weiss et al. 2003; Zorov et al. 2006).
Recent genetic studies demonstrate that opening of the PT-
pore is also important in development of heart failure
associated with dysregulated Ca2+ handling and ß-adrener-
gic receptor signaling (Nakayama et al. 2007).
The molecular entities that constitute the PT-pore
remain elusive and controversial. Historically, the PT-
pore was believed to be composed of the adenine
nucleotide translocase (ANT) in the inner membrane,
the voltage-dependent anion channel (VDAC) of the
outer membrane, and cyclophilin D (Cyp-D) in the
matrix. This classic model has, however, been brought
into question by recent genetic studies. Specifically,
neither gene deletion and/or knockdown of VDAC or
of ANT prevents PT-pore opening in response to
mitochondrial Ca2+ overload (Baines et al. 2007; Kokoszka
et al. 2004). A significant contribution of Cyp-D to PT-pore
opening was first suggested by the inhibitory effect of
cyclosporin A (Cs-A) on Ca2+-induced PT-pore opening
detected as mitochondrial swelling (Crompton et al. 1988)
and the subsequent discovery that Cs-A binds to Cyp-D
(Tanveer et al. 1996). However, as Cs-A is also a potent
calcineurin inhibitor, the mechanism of the profound
cardioprotection from I/R injury provided by Cs-A and
the role of Cyp-D in pore formation remained ambiguous
until recent studies of animals in which Cyp-D expression
was genetically manipulated. It was then determined that
mitochondria isolated from Cyp-D knockout mice are
resistant to Ca2+ overload-induced PT-pore opening, and
that Cyp-D null mouse hearts exposed to I/R show
significantly less injury than WT mice (Baines et al.
2005; Nakagawa et al. 2005). Conversely, mitochondria
isolated from transgenic mouse hearts that express elevated
Cyp-D show spontaneous pore opening (Baines et al.
2005).
While these genetic studies further defined the role of
Cyp-D in PT-pore regulation, there remains controversy
about the role of the PT-pore in apoptotic versus necrotic
death. The knockout of Cyp-D has been reported to either
have no effect on (Baines et al. 2005; Nakagawa et al.
2005), or to inhibit (Chiara et al. 2008) various forms of
apoptotic cell death in vitro. The intriguing possibility that
Cyp-D has a role in regulating apoptotic proteins in a
manner that is independent of the PT-pore has recently been
suggested (Eliseev et al. 2009), and this possibility has the
potential to resolve some of the current conflicts in the
field.
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Cardiac injury and Bcl-2 family proteins
Induction of the proapoptotic Bcl-2 family proteins is a
powerful mechanism for stimulating the mitochondrial
apoptotic pathway. Bax and Bak, both proapoptotic
members of the family, contain three Bcl-2 homology
domains (BH-domain; BH1, BH2 and BH3), but lack a
BH4 domain. The BH4 domain is critical for the
protective effect of the anti-apoptotic Bcl-2 proteins (Chen
et al. 2002) such as Bcl-2, Bcl-XL and Mcl-1. It has been
suggested that Bax and Bak permeabilize the outer
mitochondrial membrane by forming pores in response to
apoptotic stimuli. MOMP induced by Bax/Bak is further
activated in the presence of another class of proapoptotic
Bcl-2 family proteins, the BH3-only proteins (BAD, BIM,
BID, Bnip3, Nix/Bnip3L and PUMA) which facilitate Bax-
or Bak-mediated pore formation and/or antagonizing anti-
apoptotic Bcl-2 family proteins. The significance of Bcl-2
family proteins in cardiomyocyte survival and ischemic
injury has also been established (Chen et al. 2002;
Hochhauser et al. 2003; Kubli et al. 2007; Toth et al.
2006; Webster et al. 2005; Yussman et al. 2002). For
instance, Bax deletion or Bcl-2 overexpression have been
shown to protect the heart against ischemia/reperfusion
(Brocheriou et al. 2000; Chen et al. 2001; Hochhauser et al.
2003). Expression of BNip3, a BH3-only protein, is
induced by hypoxia and leads to apoptosis (Kubli et al.
2007; Webster et al. 2005) and Nix (BNip3L) is increased
in hypertrophy and triggers apoptosis in the heart (Yussman
et al. 2002). Ischemia/reperfusion-induced Ca2+ increases
and subsequent activation of calpain can also lead to
cleavage of Bid which induces cell death (Chen et al.
2002).
Akt and cardioprotection
Akt was originally described as an oncogenic protein and
extensive studies have revealed that the activity of Akt is
upregulated in many types of tumors, contributing to
diminished apoptotic cell death and facilitating tumor
growth. Akt regulates cellular metabolism, coordinated
with its pro-survival and proliferative/growth effects. Akt
is activated downstream of phosphatidylinositol 3-kinase
(PI3K) in response to stimulation of receptor tyrosine
kinases (Fujio et al. 2000; Matsui et al. 1999), glycoprotein
130(Craig et al. 2001; Kuwahara et al. 2000; Sheng et al.
1997) and G-protein coupled receptors (GPCRs) (Bell and
Yellon 2003; Chesley et al. 2000; Cohen and Downey
2008; Downey et al. 2007; Means et al. 2007; Naga Prasad
et al. 2000; Robert et al. 2001; Zhu et al. 2001) in the heart.
Akt exerts a strong cardioprotective effect in response to
activation of these receptors. Early studies using adenoviral
gene transfer directly demonstrated that Akt protects heart
against ischemia/reperfusion (Fujio et al. 2000; Matsui et al.
1999). Agonist induced Akt activation has also been
demonstrated to be cardioprotective. For example, Akt is
responsible for cardioprotection mediated by leukemia
inhibitory factor (LIF) (Miyamoto et al. 2008; Negoro et
al. 2001) or cardiotrophin-1 (CT-1) (Craig et al. 2001;
Kuwahara et al. 2000), and Akt activation by insulin or S1P
decreases I/R damage within hours in the isolated perfused
heart or in vivo (Jin et al. 2002; Jonassen et al. 2001; Means
et al. 2007). It has been also suggested that Akt is involved
in cardioprotection mediated by preconditioning, a series of
brief cycles of I/R prior to a sustained period of ischemia
(Mocanu et al. 2002; Murphy and Steenbergen 2008; Tong
et al. 2000; Uchiyama et al. 2004).
Diverse cellular Akt targets localized in various cellular
compartments confer protection through transcriptional-
(Brunet et al. 1999; Cook et al. 2002; Craig et al. 2001;
Muraski et al. 2007) and post-transcriptional regulation of
pro-survival/pro-apoptotic proteins (Datta et al. 1997; del
Peso et al. 1997; Kuwahara et al. 2000; Matsui and
Rosenzweig 2005; Pap and Cooper 1998; Shiojima and
Walsh 2006). Stimulation of receptors that activate PI3K
results in an increase in PIP3; this drives Akt translocation
to the plasma membrane where it becomes activated
through phosphorylation at T308 by the upstream kinase,
phosphoinositide-dependent kinase-1 (PDK1) and regula-
tion at S473 by TORC2 (Sarbassov et al. 2005; Williams et
al. 2000). In the cytosol, mTOR, GSK-3β and FOXO are
phosphorylated by Akt, regulating translation, transcription
and protein degradation (Matsui and Rosenzweig 2005;
Morisco et al. 2000; Shioi et al. 2002; Skurk et al. 2005). It
is now evident, however, that Akt activated at the plasma
membrane is not only active in the cytosol but also trans-
locates to subcellular compartments including the nucleus
and mitochondria (Bijur and Jope 2003; Camper-Kirby et
al. 2001; Kunkel et al. 2005; Miyamoto et al. 2008; Sasaki
et al. 2003). Translocation of activated Akt to these
subcellular components can mediate diverse effects. Redis-
tribution of activated Akt to the nucleus and to mitochondria
has been demonstrated not only by fractionation and
immunostaining but also by using FRET-based Akt activity
reporters in non-cardiac cells (Kunkel et al. 2005; Sasaki et
al. 2003). Translocation of activated Akt to mitochondria
was initially reported in neuronal cells (Bijur and Jope
2003), and we demonstrated similar translocation in
cardiomyocytes stimulated by LIF, a glycoprotein 130
receptor agonist (Miyamoto et al. 2008). Preservation
of mitochondrial integrity is known to be involved in Akt-
mediated protection (Lai et al. 2003; Miyamoto et al. 2008;
Plas et al. 2001) and several target molecules through which
Akt could afford mitochondrial protection have been
identified.
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Akt and mitochondrial protection through Bcl-2 family
proteins
Phosphorylation of Bcl-2 family proteins by Akt
Apoptosis is tightly controlled by Bcl-2 family proteins
through regulation of mitochondrial outer membrane
permeability. BAD, a BH3-only apoptotic protein, was the
first Bcl-2 family protein discovered to be phosphorylated
and regulated by Akt (Datta et al. 1997; del Peso et al.
1997). Phosphorylation of BAD by Akt at Ser 136
promotes dissociation of BAD from Bcl-XL a protective
Bcl-2 family protein. Phosphorylation of BAD at Ser136 by
agonists known to activate Akt has been demonstrated in
the heart and correlated with cardioprotection (Aikawa et
al. 2000; Jonassen et al. 2001; Kuwahara et al. 2000;
Mehrhof et al. 2001; Negoro et al. 2001; Uchiyama et al.
2004). Another Bcl-2 family protein regulated by Akt is the
proapoptotic BH1-3 protein, Bax which is a key molecule
in mitochondrial outer membrane permeabilization. Phos-
phorylation of Bax by Akt at Ser184 leads to inhibition of
the conformational change required for Bax translocation to
mitochondria (Arokium et al. 2007; Gardai et al. 2004;
Yamaguchi and Wang 2001). Phosphorylation of Bax at
Ser184 has not been reported in the heart, but deletion of
the Bax gene has been shown to decrease cardiac I/R injury
(Hochhauser et al. 2003). An inhibitory effect of Akt on
Bcl-2 family proteins has also been suggested to be
involved in the protective effect of heat shock proteins
(Hsp). Hsp27 was shown in an early study to associate with
activated Akt (Konishi et al. 1997). This observation was
extended by recent studies demonstrating that Hsp27, like
Akt, inhibits Bax activation and apoptosis and that this
occurs in a PI3K-dependent manner (Havasi et al. 2008).
Hsp20 association with Akt was also recently shown to
prolong Akt activity, leading to sustained phosphorylation
of BAD in the heart (Fan et al. 2008).
Akt and expression of Bcl-2 family proteins
In addition to modulation of activity of pro-apoptotic
proteins through phosphorylation, the expression level of
Bcl-2 family proteins is regulated by Akt. For example, LIF
treatment has been shown to work through a PI3K/Akt
pathway to prevent the doxorubicin-induced decrease in
Bcl-XL expression in cardiomyocytes (Negoro et al. 2001).
Preconditioning (which activates Akt) has also been shown
to prevent decreases in Bcl-2 expression level induced by I/
R (Uchiyama et al. 2004). Bcl-2 is also transcriptionally
upregulated by IGF-1 through CREB in an ERK- and Akt-
dependent manner (Mehrhof et al. 2001). The mTOR
complex-1 (mTORC1), which is downstream of Akt,
controls expression of the anti-apoptotic Bcl-2 family
protein Mcl-1 at the level of translation and promotes
cancer cell survival (Mills et al. 2008). FOXO has three Akt
consensus sequences and phosphorylation of FOXO by Akt
facilitates its nuclear export and thereby inhibits its
transcriptional activity. In non-cardiac cells, FOXO tran-
scription factors are known to enhance expression of Bim, a
BH-3 only protein (Dijkers et al. 2000; Gilley et al. 2003),
although the significance of Bim and its regulation by Akt/
FOXO in cardiac pathophysiology has not been established.
Taken together, there is abundant evidence that Akt exerts
transcriptional, translational, and post-translational control
of Bcl-2 family proteins which ensure that mitochondrial
integrity is preserved against short-term and long-term
stress.
GSK-3 and Akt mediated mitochondrial protection
Glycogen synthase kinase 3 (GSK-3) was initially de-
scribed in the context of glycogen synthesis, but it is now
recognized that this kinase contributes to regulation of
many other cellular functions. GSK-3 functions in the heart
as both a pro-apoptotic signal and as a suppressor of
hypertrophic responses. There are two isoforms of GSK-3
(GSK-3α and GSK-3β); GSK-3β has been most exten-
sively studied in the context of cardiac injury.
GSK-3β and Akt mediated phosphorylation
GSK-3β is an active kinase under basal conditions and Akt
phosphorylation at Ser9 inhibits the kinase activity of GSK-
3β. An earlier study by Murphy and co-workers demon-
strated that preconditioning induces phosphorylation and
inhibition of GSK-3β in a PI3K-dependent manner and that
inhibition of GSK-3β by LiCl or pharmacological inhib-
itors mimics cardiac preconditioning against I/R stress
(Tong et al. 2002). Growing evidence suggests a proapop-
totic effect of GSK-3β in the heart and demonstrates that
inhibition of GSK-3β is involved in cardioprotection mediat-
ed by ischemic pre- and post-conditioning, as well as certain
pharmacological interventions. Expression of a kinase-
inactive form of GSK-3β, acting as a dominant negative,
protects rat ventricular myocytes from isoproterenol-induced
apoptosis (Menon et al. 2007) and dominant negative GSK-
3β transgenic mice show well-compensated hypertrophy
and reduced apoptosis and fibrosis during transverse
aortic constriction (Hirotani et al. 2007). These findings
demonstrate that inhibition of GSK-3β has beneficial
effects in the heart and suggest the possibility that inhibition
of GSK-3β by Akt-mediated phosphorylation at Ser9 could
lead to cardioprotection. Indeed, a seminal study carried out
using adult ventricular myocytes revealed that insulin
inhibits ROS-induced PT-pore opening in a PI3K-
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dependent manner and this protection could be reversed by
overexpression of GSK-3β-S9A, a mutant that cannot be
phosphorylated at Ser9 (Juhaszova et al. 2004). Sollott and
co-workers also reported in this study that GSK-3β
localized not only in cytosol but also at mitochondria.
Phosphorylated GSK-3β has also been reported to be
increased at mitochondria by agonists such as insulin
(Juhaszova et al. 2004) and erythropoietin (Ohori et al.
2008), suggesting that Akt phosphorylates and inhibits
GSK-3β actions at mitochondria. This hypothesis is
supported by a recent study in which transgenic mice
expressing GSK-3β-S9A were utilized, to demonstrate that
phosphorylation of Ser9 is required for Akt-mediated
inhibition of PT-pore opening by post-conditioning in the
heart (Gomez et al. 2008).
Recent evidence provides insights into molecular mecha-
nisms by which inhibition of GSK-3β leads to mitochondrial
protection. Using perfused heart and immunoprecipitation/
Western blotting, Nishimura et al showed that GSK-3β,
phosphorylated in response to preconditioning or erythropoi-
etin treatment, interacts with ANT, leading to a decrease in
association of ANT with Cyp-D and resultant protection
(Nishihara et al. 2007). The precise mechanism by which
GSK-3β inhibition exerts protective effects at mitochondria
is controversial, however, as it has been suggested that post-
conditioning protects heart mitochondria through inhibition
of GSK-3β in a Cyp-D-independent manner and that GSK-
3β actions occur upstream of the PT-pore (Gomez et al.
2008). A paper from Steenbergen’s group proposed yet
another model in which inhibition of GSK-3β during
ischemia adapts mitochondria to ensuing reperfusion (Das
et al. 2008). Their work indicated that GSK inhibitors
prevent mitochondrial ATP consumption during ischemia
and thereby protect mitochondria against subsequent reper-
fusion. This protective effect of GSK inhibitors was
suggested to occur through decreased VDAC2 phosphoryla-
tion and inhibition of ATP transport into mitochondria. The
authors proposed that the decrease in ATP hydrolysis by
mitochondria during ischemia leads to lower mitochondrial
membrane potential, which in turn lessens Ca2+ sequestration
into mitochondria and consequent ROS generation during
reperfusion (Das et al. 2008). Thus this metabolic adjustment
induced by inhibition of GSK-3β may lead to prevention of
mitochondrial Ca2+ overload and generation of ROS, two
major inducer of the PT-pore.
Very recent studies by two different laboratories using
GSK-3α(S21A) and GSK-3β(S9A) knock-in mice suggest
that the story is more complex. Matsuda et al. (2008)
demonstrated that apoptosis induced by transverse aortic
constriction (TAC) was inhibited by knock-in of GSK-
3β(S9A). They further tested the role of phosphorylation of
GSK-3α using a non-phosphorylatable mutant of GSK-3α
(S21A) which enhanced apoptosis during TAC. These
results suggest that phosphorylation of GSK-3β at Ser9 is
pro-apoptotic whereas that of GSK-3α at Ser21 is protec-
tive (Matsuda et al. 2008). This is in sharp contrast to the
observations obtained in GSK-3β(S9A) transgenic mice in
which post-conditioning failed to protect the heart, leading
to the conclusion that phosphorylation of GSK-3β at Ser9
is cardioprotective (Gomez et al. 2008). Another recent study
demonstrated that pre-conditioning and post-conditioning
protected the heart against I/R even in GSK-3α(S21A) and
GSK-3β(S9A) double knockin mice, suggesting that neither
GSK-3α nor GSK-3-β phosphorylation at the known Akt
sites are required for pre- and post-conditioning mediated
cardioprotection (Nishino et al. 2008). Interestingly this
study showed that insulin still preserves the ability to prevent
the PT-pore in double knock-in mice, suggesting another
target of Akt for PT-pore inhibition.
In summary it is currently unclear whether phosphory-
lation and inhibition of GSK-3β by Akt confers cardiopro-
tection through inhibition of the PT-pore. The conflicting
findings in the literature might reflect the use of different
experimental models (e.g. acute inhibition by pharmaco-
logical inhibitors vs. chronic inhibition by overexpression
of mutants of GSK-3; transgenic vs. knock-in mice),
interventions to induce stress (TAC, ex vivo I/R and in
vivo I/R), and different methods for detection of the PT-
pore opening (e.g. mitochondrial membrane potential,
mitochondrial swelling, calcium retention capacity).
GSK-3β and Bcl-2 family proteins
GSK-3β has been reported to directly regulate Bcl-2 family
proteins. Mcl-1, an anti-apoptotic Bcl-2 family protein, was
originally reported by Green and co-workers to be
phosphorylated by GSK-3 and degraded, an effect that
was prevented by Akt expression (Maurer et al. 2006).
Upregulation of Mcl-1 by GSK inhibition has been recently
reported to be protective against TNF-α in cardiomyocytes
(Hirotani et al. 2007). In addition to the potential for control
of Mcl-1 protein stability through Akt/GSK-3β, Mcl-1 is
transcriptionally up-regulated in response to Akt activation
through mTOR signaling and promotes tumor cell survival
(Mills et al. 2008). GSK-3β also phosphorylates Bax and
induces an activating conformational change, a response
that has been shown to be inhibited by Akt in neuronal cells
(Linseman et al. 2004) and in yeast (Arokium et al. 2007).
Similarly, in H9c2 cells, H2O2-induced BAX translocation
to mitochondria was attenuated when GSK-3β was
knocked down by siRNA or when cells were stimulated
with erythropoietin, an Akt agonist (Ohori et al. 2008). It
has also been reported that GSK-3 inhibitor treatment
increases the association of Bcl-2 with mitochondria in the
heart (Das et al. 2008). Taken together, there are a multitude
of possible mechanisms through which GSK-3β could
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mediate the protective effects of Akt on cell survival in the
heart.
Hexokinase-II and Akt mediated mitochondrial
protection
Hexokinase (HK) catalyzes the first step of glycolysis,
phosphorylating glucose to glucose-6-phosphate, and is
therefore of fundamental importance in cellular metabolism
and physiology. There are four isoforms of HK (I, II, III
and IV). HK-I and HK-II have mitochondrial binding
motifs at their N-terminus and are reported to bind to
the outer mitochondrial membrane through VDAC
(Anflous-Pharayra et al. 2007; Azoulay-Zohar et al.
2004; Nakashima et al. 1986; Pastorino et al. 2005). HK-I
is ubiquitously expressed and HK-II, while also widely
expressed, is the predominant isoform in insulin sensitive
tissues such as adipose, skeletal and cardiac muscle and in
most cancer cells (Pastorino and Hoek 2003; Wilson 2003).
Pedersen’s laboratory has suggested that mitochondrial
HKs play a role in facilitating ATP production through
the preferential access of this enzyme to ATP generated
by mitochondria, resulting in more efficient glycolysis
(Mathupala et al. 2006; Pedersen 2007). Elevated glycol-
ysis even in the presence of oxygen is one of the hallmark
changes in metabolism associated with cancer cells, and
was classically described as the Warburg Effect (Pastorino
and Hoek 2003; Pedersen 2007).
There is increasing evidence that energy metabolism and
cell survival utilize common pathways in many organ
systems, and key amongst these is the recognition that Akt
regulates metabolism as well as cell survival (Matsui and
Rosenzweig 2005; Pastorino and Hoek 2003). Akt-
mediated protection of cardiomyocytes against I/R is
accompanied by enhanced sarcolemmal Glut-4 expression
and glucose uptake (Matsui et al. 2001). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), a glycolytic enzyme,
mediates not only changes in glycolysis but also protects
cells from caspase-independent cell death (CICD) by
enhancing autophagy (Colell et al. 2007). Of further
interest, the apoptotic and metabolic machinery share
certain signaling molecules (Galluzzi et al. 2008). For
instance, a physiological/metabolic role of the proapoptotic
Bcl-2 family protein BAD has been revealed in pancreatic
beta cells in which phosphorylation of BAD at Ser155
inhibits its apoptotic effect but concomitantly increases
glucose-fueled mitochondrial respiration (Danial et al.
2008). This increase in mitochondrial metabolism enhances
glucose-stimulated insulin secretion from the beta cells by a
mechanism that involves binding and stimulation of
glucokinase (the HK IV isoform mainly expressed in
pancreas and liver) by phosphorylated BAD (Danial et al.
2008). Whether a similar mechanism for maintenance of
optimal glucose metabolism in heart could be mediated
through an interaction of phosphorylated BAD with
hexokinase II is not yet known.
Mitochondrial HK-II and the pro-survival effect
There is accumulating evidence that HKs play a role in
protective as well as glycolytic signaling. Treatment of cells
with heparin-binding epidermal growth factor (HB-EGF)
increases cellular HK activity in renal epithelial cells and
expression of HK-I by adenovirus protects against acute
oxidant-induced epithelial cell death (Bryson et al. 2002).
Similarly, retroviral overexpression of HK-II in lung
epithelial-like A549 cells is protective against oxidative
injury and this overexpressed HK-II is localized to
mitochondria (Ahmad et al. 2002). There is also evidence
for HK protection in experiments with isolated mitochon-
dria. Addition of purified mammalian HK-I to mitochondria
from rat liver, which do not express mitochondria-
associated HKs ,was shown to prevent Ca2+-induced
mitochondrial swelling and cytochrome c release. In
contrast addition of yeast HK lacking the ability to bind
to mitochondria was not protective (Azoulay-Zohar et al.
2004). These data indicate that mitochondrial HKs have an
inhibitory effect on Ca2+-induced PT-pore opening. Support
for a role of endogenous HKs in protection comes from the
observation that dissociation of HK-II from mitochondria
sensitizes fibroblast to apoptotic death (Majewski et al.
2004a) and induces apoptosis in Hela cells through a PT-
pore opening (Chiara et al. 2008). Taken together, these
results provide support for the idea that mitochondrial HK-I
and HK-II have the ability to protect mitochondria against
ROS or Ca2+ overload, two well-known PT-pore inducers.
HK-II also protects against apoptosis induced by Bcl-2
family proteins such as Bax by competitive inhibition of
Bax binding to VDAC (Majewski et al. 2004a; Pastorino
and Hoek 2003; Pastorino et al. 2002; Robey and Hay
2006).
The role of HK-II in cardioprotection has not been fully
considered although HK-II is abundantly expressed in the
heart. Several recent studies have demonstrated a protective
role of mitochondrial HKs in cardiomyocytes (Chiara et al.
2008; Miyamoto et al. 2008; Sun et al. 2008). Over-
expression of full length HK-I or HK-II was shown to
protect against H2O2-induced mitochondrial depolarization
in neonatal rat ventricular myocytes (NRVMs) (Sun et al.
2008). Decreased protection was observed using either
mutants lacking the mitochondrial binding motif or kinase-
dead HK-I or HK-II (Sun et al. 2008), implicating
mitochondrial binding and the catalytic activity of hexoki-
nase in protection of NRVMs. Chiara et al. (2008)
demonstrated that dissociation of mitochondrial HK-II
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increases susceptibility of adult ventricular myocytes to
ROS induced PT-pore opening (Chiara et al. 2008). Our
work was the first to report that HK-II is phosphorylated by
Akt and plays a significant role in Akt-mediated protection
against Ca2+ overload in isolated heart mitochondria and
against H2O2-induced injury of NRVMs (Miyamoto et al.
2008), as described below.
Mitochondrial HKs and Akt mediated protection
The protective effect of mitochondrial HK-II has been
linked to the PI3K/Akt signaling axis (Gottlob et al. 2001;
Majewski et al. 2004a; Pastorino and Hoek 2003; Pastorino
et al. 2002; Rathmell et al. 2003; Robey and Hay 2006).
Hay and co-workers demonstrated that expression of
membrane targeted constitutively activated Akt (myristoy-
lated-Akt; myr-Akt) increased mitochondrial HK activity in
Rat1a fibroblasts and suggested that HK was involved in
Akt-mediated cell survival (Gottlob et al. 2001). Cells were
protected against growth factor withdrawal and UV
exposure, and adenoviral HK-I expression mimicked the
protective ability of myr-Akt. It has also been shown that
Akt inhibits tBid-induced apoptosis through increased
mitochondrial HK activity, antagonizing tBID-mediated
BAX and BAK activation at mitochondria (Majewski et
al. 2004b). Interestingly, disruption of mitochondrial HK-II
association impaired myr-Akt-mediated protection even in
the absence of Bax and Bak, critical mediators of MOMP.
This strongly suggests that Akt/mitochondrial HK-II has the
ability to prevent cell death induced by mechanisms beyond
those that regulate Bcl-2 family proteins and MOMP.
Recent work from our laboratory suggested that mito-
chondrial HK-II plays a crucial role in Akt-mediated
inhibition of the PT-pore in cardiomyocytes (Miyamoto et
al. 2008). In our study, endogenous Akt was activated by
LIF, shown to accumulate at mitochondria and implicated
in phosphorylation of mitochondrial HK-II. HK-II has an
Akt consensus sequence (RxRxxS/T) that is conserved in
rat, mouse and human. The appearance of phosphorylated
Akt at mitochondria was associated with increased mito-
chondrial HK-II. Dissociation of HK-II from mitochondria
diminished the protective effects of LIF against H2O2-
induced mitochondrial depolarization in NRVMs. Addition
of recombinant active Akt to mitochondria isolated from
adult mouse heart inhibited Ca2+-induced cytochrome c
release and this effect was reversed by dissociation of HK-
II from the mitochondria. Thus phosphorylation of mito-
chondrial HK-II appears to underly Akt-mediated PT-pore
inhibition in cardiomyocytes. A similar observation was
recently reported in Hela cells where insulin, a strong
Akt activating agonist that normally prevents cell death,
was unable to antagonize cell death induced by HK-II dis-
sociation from mitochondria (Chiara et al. 2008). These
results provide strong support for the idea that mitochondrial
HK-II is a critical effector of Akt-mediated mitochondrial
protection.
It is of interest that mitochondrial HK activity in the
heart is increased by interventions known to activate Akt,
including insulin, preconditioning and morphine (Russell et
al. 1992; Zuurbier et al. 2005), although conflicting data
has been shown (Doenst et al. 1998). An immunogold
labeling study further demonstrated that insulin increases
mitochondrial association of HK-I and HK-II and the
finding that the increase is greater for HK-II than HK-I
suggested differential regulation of distribution of these two
mitochondrial HKs (Southworth et al. 2007). This is of
particular interest as we found that there is an Akt
phosphorylation consensus sequence in mouse, rat and
human HK-II but not in HK-I (or HK-III). Thus Akt-
mediated phosphorylation and regulation of hexokinase
distribution might be specific to HK-II. It will be of interest
to investigate whether the Akt/HK-II pathway plays a
significant role in preservation of heart integrity against
stress such as ischemia/reperfusion in vivo.
There is evidence that Akt also regulates the expression
of HK-II at the transcriptional level. Insulin treatment was
shown to increase HK-II mRNA in adipose and skeletal
muscle cell lines (Printz et al. 1993). A subsequent study by
the same group showed that insulin induced upregulation of
HK-II but not HK-I and this induction of HK-II was
inhibited by PI3K blockers or rapamycin, suggesting a
contribution of PI3K/Akt and mTOR to induction of HK-II
mRNA by insulin (Osawa et al. 1996). Similar observations
were reported by other groups examining the effect of
insulin in 3T3-L1 adipocytes (Culbert and Tavare 2002)
and colony-stimulating factor-1 in myeloid cells (Lee and
States 2006). We also observed that HK-II protein
expression is increased in NRVMs in response to 48 h
LIF treatment or overexpression of wild-type Akt (unpub-
lished observation), consistent with a role for Akt in HK-II
upregulation in the heart. Thus, in addition to acute
regulation of mitochondrial HK-II through phosphorylation,
the upregulation of HK-II induced by Akt activation may
contribute to protective effects of Akt under chronic stress.
How does mitochondrial HK-II prevent PT-pore opening?
Although protective roles of mitochondrial HKs have been
clearly demonstrated, the mechanism by which mitochon-
drial HK-I and HK-II protect mitochondria are not clear.
Mitochondrial HK has preferential access to ATP generated
by mitochondria and the ADP produced by this reaction can
be transported back into mitochondria by the ANT and used
as a substrate by F1F0 ATP synthase to produce ATP (ADP
recycling). By providing mitochondria with a constant
supply of ADP (presuming an adequate supply of inorganic
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phosphate), mitochondria can slightly depolarize the mem-
brane and can thus minimize ROS production by the
electron transport chain (da-Silva et al. 2004). This could
contribute to protection, although this needs to be experi-
mentally proven especially under stressed conditions. In
fact, apoptosis induced by HK-II detachment from mito-
chondria was prevented by deletion or inhibition of Cyp-D
or inhibition of the ANT, but not by an F1F0 ATP synthase
inhibitor (Chiara et al. 2008). While VDAC is an
established binding partner of HK-II at the OMM, it has
been shown using VDAC KO MEF cells that VDAC is not
involved in apoptosis induced by HK-II dissociation
(Chiara et al. 2008).
Interestingly, pharmacological inhibition or knockdown
of Cyp-D resulted in release of HK-II from mitochondria
(Chiara et al. 2008; Machida et al. 2006), suggesting that
Cyp-D stabilizes mitochondrial HK-II binding. Cyp-D and
HK-II have both been postulated to be regulatory compo-
nents of the PT-pore. Gene deletion of Cyp-D blocks PT-
pore opening and conversely overexpression of Cyp-D
induces mitochondrial swelling and cell death in the heart
(Baines et al. 2005). In contrast to the stimulatory role of
Cyp-D in PT-pore induction in the heart, mitochondrial
HKs play an inhibitory role in PT-pore opening. These
positive and negative regulators appear to interact with each
other to regulate pore opening. However, it remains unclear
which molecule(s) mediate the interaction of these two PT-
pore regulators. Cyp-D is a mitochondrial matrix protein
and HK-II binds to the OMM thus it is unlikely that they
physically interact. Cyp-D and HK-II bind to ANT and
VDAC respectively, but the recent exclusion of these
proteins as necessary for PT-pore opening clearly suggests
that other proteins must be involved in HK-II and CypD-
mediated protection. Recent data suggests that the phos-
phate carrier binds to CypD, and this inner membrane
transporter has been implicated in formation of the PT pore
(Alcala et al. 2008; Leung et al. 2008). As well, phosphate
has recently been shown to be required for inhibition of PT-
pore formation by CsA or by CypD ablation (Basso et al.
2008), which may imply regulation of phosphate carrier
conformation by the presence of its substrate. Recently, Cyp-
D was suggested to directly bind to Bcl-2 (Eliseev et al.
2009), which would require Bcl-2 to be localized to and span
the inner membrane. New avenues of exploration will need
to be pursued to identify the full complement of proteins
involved in HK-II-mediated protection of mitochondria.
Upstream of mitochondrial PT-pore formation:
Inhibition of cytosolic Ca2+ overload by Akt
Cytosolic Ca2+ concentration is tightly regulated such that
the intracellular Ca2+ concentration is kept at 100 nM~
1μM, one to ten thousands fold lower than that in the
extracellular space. Dysregulation of Ca2+ handling leads to
cytosolic Ca2+ overload, followed by excessive mitochon-
Fig. 1 Akt preserves mitochon-
drial integrity against stress
through multiple target mole-
cules in the heart
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drial Ca2+ sequestration and PT-pore opening. Akt appears
able to prevent Ca2+ overloading under pathophysiological
settings. For instance, we have found that LIF pre-treatment
dramatically dampens the increase in cytoplasmic Ca2+ in
NRVMs treated with H2O2 (unpublished observation), and
we previously reported that myr-Akt expression in NRVMs
reversed the decrease in expression of Na+/Ca2+ exchanger1
(NCX1) induced by constitutively active Gqα (Q209L)
expression. NCX1 is responsible for Ca2+ extrusion from
the cytoplasm in cardiomyocytes. Akt-mediated preserva-
tion of NCX1 expression prevents cytoplasmic Ca2+
overload, opening of the PT-pore and apoptosis induced
by Q209L(Miyamoto et al. 2005). Akt-mediated transcrip-
tional up-regulation of NCX1 and NCX3 has recently also
been reported in a study on PC12 cells which further
supports the idea that enhanced Ca2+ extrusion via NCX
contributes to Akt-mediated protection (Formisano et al.
2008). Interestingly, the cardiac Na+/H+ exchanger (NHE)
has been discovered to be phosphorylated by Akt leading to
inhibition of its activity (Snabaitis et al. 2008). NHE
imports Na+ ions and exports H+ ions in response to
acidosis during ischemia. The resultant intracellular accu-
mulation of Na+ ions, in turn, reverses NCX ion transport to
the Ca2+ import mode, leading to cytosolic Ca2+ over-
loading. NHE inhibition during I/R has been established to
be protective in many experimental models (Avkiran et al.
2008) and NHE phosphorylation and inhibition mediated
by Akt would provide a molecular mechanism for preven-
tion of cytoplasmic Ca2+ overloading in the heart.
Another interesting new finding is that Akt phosphor-
ylates type-I IP3 receptors (IP3R) which inhibits Ca
2+
release from the ER and prevents Ca2+ induced apoptosis
in non-cardiac cells (Khan et al. 2006; Szado et al. 2008). A
consensus sequence for Akt phosphorylation (RxRxxS/T) is
present in all three types of IP3Rs. Although the contribu-
tion of IP3Rs to cardiac Ca
2+ regulation has been thought to
be minimal, there is compelling evidence that Ca2+ release
from IP3Rs can regulate cardiac cellular functions including
positive inotropy, gene expression, induction of arrhythmia
and regulation of pacemaking (Domeier et al. 2008;
Kockskamper et al. 2008; Roderick and Bootman 2007;
Woodcock et al. 2008; Wu et al. 2006). Therefore, it is
probable that IP3-induced Ca
2+ release plays a role in
regulation of mitochondrial Ca2+, as observed in NRVMs
stimulated with ATP (Jaconi et al. 2000) and in the heart
(Garcia-Perez et al. 2008). ER/SR Ca2+ overloading has
been receiving increasing attention in the context of
regulation of cell death, since ER/SR Ca2+ pools commu-
nicate with mitochondria due to the proximity of release
site and mitochondria (Diwan et al. 2008; Garcia-Perez et
al. 2008; Jaconi et al. 2000; Szalai et al. 1999). Notably,
IP3R expression is increased in heart disease (Go et al.
1995), thus IP3R signaling and its regulation by Akt may
have increased importance in regulation of mitochondrial
Ca2+ and cardiomyocyte survival under pathophysiological
conditions. Finally, it is becoming clear that Bcl-2 family
proteins not only function at mitochondria but also localize
to and control the Ca2+ content of intracellular Ca2+ pools
(Pinton and Rizzuto 2006). Apoptotic Bcl-2 family mem-
bers such as Bax, Bak and Nix localize at ER/SR and
increase their Ca2+ content, resulting in large increases in
Ca2+ release and subsequent mitochondrial Ca2+ over-
loading (Demaurex and Distelhorst 2003; Diwan et al.
2008; Nutt et al. 2002; Scorrano et al. 2003). In contrast,
anti-apoptotic Bcl-2 family proteins decrease ER Ca2+
content and Ca2+ release (Demaurex and Distelhorst 2003;
Palmer et al. 2004). It will be of considerable interest to
determine whether Bcl-2 family proteins play a role in SR-
mitochondrial Ca2+ crosstalk in the heart, as demonstrated
in Nix mediated cardiac cell death (Diwan et al. 2008), and
whether Akt-mediated phosphorylation of Bcl-2 family
proteins can lead to change in their ER/SR localization.
Conclusion
Akt provides a strong survival signal in various cell types
including cardiomyocytes and exerts its protective effects
through phosphorylation of diverse target molecules such
as Bcl-2 family proteins, GSK-3β and, as recently
demonstrated HK-II (Fig. 1). Preservation of mitochondrial
integrity is critical for regulation of metabolism and cell
survival, and recent compelling evidence indicates that Akt
can serve as an integrator and gatekeeper of both of these
mitochondrial functions.
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